Healthcare / BiotechnologyNasdaqCM
$3.55
-0.19 (-5.08%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-15.7M · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$45M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-262.0%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-17.1M · FCF $-15.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Net Income | $-17.1M | $-17.1M | $-20.8M | $-16.0M | $-14.3M | $-12.4M | $-5.9M | $-2.4M |
| EBITDA | $-18.0M | $-18.0M | $-22.2M | $-17.9M | $-14.4M | $-12.6M | — | — |
| EPS | — | — | -1.93 | -1.47 | -1.31 | -1.13 | — | — |
| Balance Sheet | ||||||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | — | — | — |
| Current Ratio | 1.87 | 1.87 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-15.7M | $-15.7M | $-17.8M | $-14.4M | $-12.8M | $-10.6M | — | — |
| Returns | ||||||||
| ROE | -262.0% | -262.0% | -98.1% | -39.0% | -25.4% | -17.3% | -30.0% | -257.4% |
| Valuation | ||||||||
| P/B | 6.11 | 6.11 | 1.90 | 1.10 | 1.07 | — | — | — |
| Growth & Yield | ||||||||
| EPS Growth | — | — | -31.3% | -12.2% | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+11.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.93 → n/d
Residual
+11.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.